Key Points
- Neurologist Dr. Ki Jung called gabapentin and Lyrica the "staple or first-line treatment options for neuropathy," and Medicare lists anticonvulsants and antidepressants as protected drug classes.
- The Centers for Medicare & Medicaid Services puts the Part D yearly out-of-pocket limit at $2,100 in 2026, and MVP Health Care's 2027 formulary page lists $2,400.
- In 2022, KFF reported that people in Traditional Medicare paid 20% coinsurance for Part B drugs given by a provider, with no annual limit on what they could owe.
Short answer: Drugs for Peripheral Neuropathy: What Each Type Treats and How Medicare Covers Them is a Medicare care-navigation topic and refers to the practical steps explained in this guide. See which nerve pain drugs doctors try first, how Medicare drug plans pick drugs and tiers, and where clinic treatments shift your costs to Part B. Understood Care advocates have helped thousands of members with drugs for peripheral neuropathy:. Compared to generic medical helplines, our advocates work one-to-one across 50 states.
Quick Answer
Doctors often start with gabapentin, Lyrica or an antidepressant such as Cymbalta. Your Part D plan covers these drug classes, but each plan picks the drugs and tiers.
Some drugs stay off a plan's list. Health Net's drug list says certain drugs are left out for clinical and cost reasons. Nerve blocks, shots and stimulation devices fall under Part B and local coverage rules, where I would watch first for a bill with no yearly ceiling in Original Medicare. Understood Care confirms coverage for each person before the first appointment.
Nerve pain medicines and Medicare drug lists often get sorted out together at the kitchen table.
No drug plan covers every medicine, and the ones it does cover can come with limits or extra rules. For nerve pain, that means two people with the same diagnosis may pay very different amounts.
Three things shift the bill. Which plan you have. Where the treatment happens. And where you live.
That last one surprises people most. A CMS billing and coding article for nerve blocks and electrostimulation, which applies through the Medicare contractors serving states including Alabama, Georgia, Tennessee and Virginia, lists no neuropathy diagnosis that supports medical necessity for those treatments. A neighbor in another state may face different local rules for the very same procedure.
Getting help can depend on geography too. In Utah, Understood Care accepts Medicare Advantage plans from UnitedHealthcare, which held 40% of the state's Medicare Advantage members on 2024 enrollment, and about 69% of Utah's Medicare Advantage members are with an insurer Understood Care accepts. In Wyoming, Understood Care does not currently accept a Medicare Advantage plan and works with Original Medicare instead. Either way, coverage is confirmed for each person before the first appointment.
I think these local details matter more than most drug guides admit, because a list of medicine names cannot tell you what your own plan, in your own state, will actually pay. It can help to keep your plan card and your state in mind as you read. The next step is knowing which medicines are on the table at all, starting with the ones doctors try first.
The burning. The pins and needles. The numb feet that make the stairs feel uncertain. If you live with peripheral neuropathy, or care for someone who does, the pain is only half the worry. The other half often shows up at the pharmacy counter.
Here is some steadier ground first. The medicines doctors reach for most, such as gabapentin, Lyrica, duloxetine and amitriptyline, belong to drug families that every Medicare drug plan is required to carry. Medicare.gov names anticonvulsants and antidepressants among its protected classes. What changes from plan to plan is the exact drug, its tier and the rules attached to it.
Where you get a treatment matters just as much. Pills you take at home run through Part D. Shots and infusions that a provider gives you in an office usually fall under Part B, with its own deductible and coinsurance. Those two paths can lead to very different bills for the same condition, and prices keep moving: Medicare's negotiated prices for its first 10 Part D drugs took effect January 1, 2026, and 15 more take effect January 1, 2027.
I believe most families can handle all of this once the pieces are laid out plainly. So the place to start is the drugs themselves, and what each one is meant to help.
Which drugs do doctors try first for peripheral neuropathy?
Doctors usually start with gabapentin, Lyrica, duloxetine or amitriptyline. As Part D drugs in 2026, your yearly out-of-pocket cost for them stops at $2,100.
If you are just starting treatment, it can help to sort your options in this order:
- Ask your doctor which first-line drug fits your symptoms and other health conditions.
- Ask whether a generic version is available.
- Check that exact drug on your plan's drug list before you fill it.
- Write down how you feel each week so your next visit is easier.
Neurologist Dr. Ki Jung, speaking on the Back Talk Doc podcast, called gabapentin and Lyrica the "staple or first-line treatment options for neuropathy." Both began as antiseizure medicines. Dr. Jung explained that nerve cells and brain cells develop in similar ways, so a drug that calms "short circuiting" in the brain can often calm misfiring nerves too. These drugs do not repair the nerve. They change how strongly you feel the burning, tingling or pins and needles.
Antidepressants sit right beside them. Dr. Jung named older ones like amitriptyline and newer ones like Cymbalta (duloxetine). The common assumption is that a doctor prescribes these only for low mood. In fact, they act on brain chemicals that shape how you sense nerve pain. You do not need to be depressed for one to help.
| Drug type | Examples | What it is meant to help with |
|---|---|---|
| Antiseizure (anticonvulsant) | Gabapentin, Lyrica (pregabalin) | Calming overactive nerve signals behind burning and tingling |
| Antidepressant | Duloxetine (Cymbalta), amitriptyline | Changing how the brain processes nerve pain |
| Second-line pain medicine | Typical pain relievers your doctor chooses | Added relief when first-line drugs are not enough |
The research points the same way. A narrative review by Jones and colleagues in Current Clinical Pharmacology found that duloxetine and gabapentin decreased nerve pain in people whose neuropathy was caused by other medicines. A market report on neuropathy treatment makes a similar claim, describing antidepressants and anticonvulsants as the first approach to nerve pain. Across 5 sources reviewed here, the pattern holds steady. Antiseizure and antidepressant medicines come first.
In practice, this means you have more than one starting option. If the first drug causes side effects, many people find a second one works better. It may take time to find the right fit, and that is normal.
I want families to know that help with the paperwork side is available wherever you live. In Wyoming, for example, Understood Care works with people on Original Medicare, even though we do not currently accept a Medicare Advantage plan there. If you are weighing whether outside help makes sense, our guide on choosing a Medicare patient advocate walks through what to look for. Once you and your doctor pick a drug, the next question is which part of Medicare pays for it.
Will your Medicare drug plan cover the nerve pain medicine your doctor picks?
In short: Will your Medicare drug plan cover the nerve pain medicine your doctor picks?: Most likely, yes, but each plan picks the exact drugs and what you.
Most likely, yes, but each plan picks the exact drugs and what you pay. Under a standard 2026 Part D plan, you pay full price until you meet a $615 deductible.
That deductible figure comes from the Centers for Medicare & Medicaid Services, and it is the most a standard plan can charge. Some plans set a lower one. It can feel unfair to pay so much in January for a pill you took all of last year. If the first pharmacy receipt of the year catches you off guard, you are not alone.
Here is the part that often brings some relief. Medicare.gov explains that every drug plan has to carry at least 2 drugs in the most commonly prescribed classes, and it names anticonvulsants and antidepressants among the protected classes that plans are required to include. Those two families hold gabapentin, Lyrica, duloxetine and amitriptyline. So the family will be there. Your exact drug is another matter, because each plan chooses which specific drugs it offers.
Where a drug lands on the plan's drug list, called a formulary, shapes your copay. A typical setup puts most generics on Tier 1 with the lowest copay, preferred brands on Tier 2, non-preferred brands on Tier 3 and very high-cost drugs on a specialty tier. Some insurers describe their own plans as stretching to five tiers. A generic and a brand-name nerve pain drug can sit several tiers apart on the same plan.
Plans also leave some drugs off on purpose. Health Net's formulary says plainly that some drugs are not on its list "because of clinical and cost reasons." It also notes that during the year, generally with advance notice, the plan can:
- add or remove drugs
- move a drug to a higher or lower cost-sharing tier
- add or remove coverage restrictions
- replace a brand-name drug with a generic
What does this mean for you? Check your exact drug, not just its family. Check its tier, too.
I'd gently suggest keeping your plan's change notices next to your pill bottles instead of tossing them out with the catalogs and flyers that crowd the mailbox every fall. Small paperwork details carry real weight in Medicare, a lesson that also shows up in why most utility allowance denials trace to one missing form. And if your drug is missing from the list or sits on a costly tier, your prescriber can ask the plan for an exception, backed by a written statement of the medical reason.
What if neuropathy medicines don't help enough, and will Medicare pay for other treatments?
In short: Office treatments are billed under Part B, not Part D, and some face strict local rules.
Office treatments are billed under Part B, not Part D, and some face strict local rules. "Will Medicare pay for it?" was the top coverage question our team handled: 984 asks.
It's common to reach a point where the pills help only a little, or bring side effects that are hard to live with. Many people then ask about treatments given in a doctor's office or hospital clinic. That is a different kind of bill. Our team hears the payment question more than any other, and here the honest answer often depends on where you live.
A CMS billing and coding article, A56731, works alongside Local Coverage Determination L37642 and covers nerve blocks and electrostimulation for peripheral neuropathy. Its version effective January 1, 2024 lists 129 neuropathy diagnosis codes, including diabetic and drug-induced neuropathy, as codes that do not support medical necessity for these treatments. It applies through the Medicare contractors for Jurisdictions J and M, which cover Alabama, Georgia, Tennessee, North Carolina, South Carolina, Virginia and West Virginia. In plain words, Medicare there treats these procedures as not medically necessary for neuropathy pain. Ask before you book.
There is a newer, gentler option. Transcutaneous magnetic peripheral nerve stimulation sends focused, low-frequency magnetic pulses to a nerve through the skin, with no needles. It is meant for adults 18 and older, including people with chronic painful diabetic neuropathy in the legs and feet.
In its 2027 hospital outpatient rule, published November 6, 2026, CMS keeps this therapy under its own billing codes, 0766T and 0767T, with separate payment in hospital outpatient departments. The same rule expands prior authorization, meaning advance approval from Medicare, to more botulinum toxin injection services starting January 1, 2027. If your doctor suggests one of those injections, expect a paperwork step first.
Before you agree to any office treatment, it can help to ask your doctor's billing office these four questions:
- Is this billed to Part B, and is it covered in my state?
- Does it need prior authorization, and who sends the request?
- What will I owe if Medicare does not pay?
- Is there another medicine, or a different dose, we have not tried yet?
Approval steps can stretch out in many corners of Medicare, as families learn when they read about how Advantage plans slow-walk lift chair approvals. So I'd ask one more thing at the front desk: who files the request, and on what day, before the appointment ever lands on your calendar.
Where could nerve pain costs keep climbing under Medicare?
In short: Where could nerve pain costs keep climbing under Medicare?: Most worry about neuropathy coverage centers on the pills.
Most worry about neuropathy coverage centers on the pills. When we followed Medicare's own rules, the pills turned out to be the steadier part of the bill, and the open-ended risk sat elsewhere.
The first-line drugs sit in protected territory. On the Back Talk Doc podcast in 2022, neurologist Dr. Ki Jung noted that gabapentin and Lyrica "were originally actually anti-seizure medications," and named amitriptyline and Cymbalta among the antidepressants doctors also reach for first. Medicare lists anticonvulsants and antidepressants as protected classes: "all plans must include most drugs in certain protected classes on their drug list." An ordinary category needs only at least 2 drugs. Plans still set tiers and rules. Humana's member guide notes that a formulary exception can ask a plan to waive step therapy or quantity and dosage limits, and Medicare lets a prescriber request one with a supporting statement explaining the medical reason.
The real leak appears outside the plan. According to the Centers for Medicare & Medicaid Services, the Part D yearly limit is $2,100 in 2026, and a 2027 formulary page from MVP Health Care puts it at $2,400 next year. Paying for off-list drugs "does not count towards your plan deductible or annual out-of-pocket max," Humana's guide says. Medicare.gov says purchases with TrumpRx or similar discount cards don't count either. A lower cash price at the counter can still leave you further from the ceiling.
| Pharmacy pills (Part D) | Office or hospital outpatient treatments (Part B) | |
|---|---|---|
| Who decides | Your plan's drug list, which must include most protected-class drugs | Medicare rules plus regional billing guidance |
| Your share | Plan tiers and deductible | Usually 20% of the approved amount after the $283 deductible (2026) |
| Yearly limit | $2,100 in 2026, $2,400 in 2027 | None in Original Medicare without supplemental coverage. Medicare Advantage plans set their own |
| What doesn't count | Off-list drugs and discount-card purchases | Services Medicare doesn't cover |
Clinic treatments have no such ceiling. In Original Medicare, Medicare.gov says, "There's no yearly limit on what you pay out-of-pocket, unless you have supplemental coverage" such as Medigap, Medicaid or retiree coverage. KFF, the health policy research organization, counted "roughly 6 million Medicare beneficiaries" without supplemental coverage. Its analysis of 2019 claims covers all Part B drugs, including cancer and eye drugs, and has no neuropathy breakdown. It still shows how large an uncapped share can get.
Before any 20% applies, Medicare has to agree to pay at all. A billing article on nerve blocks and electrostimulation for peripheral neuropathy, used by the contractors for Alabama, Georgia, Tennessee, South Carolina, Virginia, West Virginia and North Carolina, lists 129 diagnosis codes that "DO NOT Support Medical Necessity." They include type 2 diabetes with diabetic polyneuropathy, and drug-induced polyneuropathy, the category covering nerve damage from medicines such as chemotherapy. The supporting list holds only a placeholder marked "Not Applicable." The version we read, revised January 1, 2024, has since been superseded.
One device does have a payment pathway. CMS hospital outpatient rules for 2025, 2026 and 2027 describe transcutaneous magnetic peripheral nerve stimulation for "chronic painful diabetic peripheral neuropathy in the lower extremities for patients 18 and older," billed under codes 0766T and 0767T. A payment class sets how a hospital gets paid. Whether your own claim is approved is a separate decision, and the service still falls under Part B. The science is also unsettled: a narrative review by Jones and colleagues called neuromodulation "quite promising" but said more randomized controlled studies are needed.
Side by side, the rules sort neuropathy costs by where you are treated. The ceiling protects you at the pharmacy counter, then stops at the edge of the drug list and at the clinic door, where local rules tighten and newer devices are still being tested. Our call data shows the questions reach well past pills. After "Will Medicare pay for it?", the coverage question our team handled most was "Can I get shoes for my neuropathy?", asked 573 times. Ask about each treatment separately.
- Before paying cash or using a discount card for a nerve pain drug, ask your plan whether a listed drug in the same class would work, because cash purchases don't count toward the yearly limit.
- If your drug is off the list or faces step therapy or quantity limits, ask your prescriber to request an exception with a supporting statement before you pay full price.
- Before an office or hospital outpatient treatment, ask whether it is billed under Part B, what your 20% is likely to be, and whether Medigap, Medicaid or retiree coverage will pick it up.
- In those seven states, ask the clinic to check the current version of billing article A56731 before you agree to nerve blocks or electrostimulation, and ask what you would owe if Medicare does not pay.
- If magnetic nerve stimulation is offered, ask whether your diagnosis matches the indication CMS describes and whether the clinic expects Medicare to approve it in your case.
How we checked this
We read Medicare.gov coverage pages, CMS fact sheets, a CMS billing article and three CMS hospital outpatient payment rules, a 2022 KFF analysis, member pages from two insurers (Humana and MVP Health Care, both of which sell Medicare drug plans), a 2022 neurology podcast and a news summary of a narrative review. The 573 shoe questions come from our own team's call records. KFF's cost figures date from 2019 and cover all Part B drugs, with no breakdown for neuropathy. The billing article we read is a superseded version, and a payment rule does not show whether an individual claim will be approved. We help people with Medicare navigate coverage, so we have a stake in how these questions are answered. Still unknown: how often Medicare actually pays for magnetic nerve stimulation for neuropathy, and what neuropathy patients typically owe under Part B.
- Medicare.gov, how Medicare drug plans work, undated.
- Medicare.gov, help with drug costs and discount cards, undated.
- Medicare.gov, comparing Original Medicare and Medicare Advantage, retrieved November 10, 2026.
- Medicare.gov, Part B outpatient prescription drugs, undated.
- Centers for Medicare & Medicaid Services, final CY 2026 Part D redesign instructions, checked September 25, 2026.
- Centers for Medicare & Medicaid Services, 2026 Part A and B premiums and deductibles, checked September 25, 2026.
- Humana, explainer on Part D formularies, updated January 16, 2026.
- MVP Health Care, 2027 Medicare drug formulary page, October 2026.
- KFF, analysis of Part B drug costs for beneficiaries, March 15, 2022.
- CMS Medicare Coverage Database, billing article A56731 on nerve blocks and electrostimulation, revision effective January 1, 2024 (superseded).
- Federal Register, CY 2025 hospital outpatient payment rule, November 27, 2024.
- Federal Register, CY 2026 hospital outpatient payment rule, November 25, 2025.
- Federal Register, CY 2027 hospital outpatient payment rule, November 6, 2026.
- Back Talk Doc podcast, interview with neurologist Dr. Ki Jung, September 8, 2022.
- Medznat, summary of a narrative review on drug-induced neuropathy, September 1, 2020.
- Understood Care, internal call records on coverage questions, 2026.
What should you keep in mind as you plan for nerve pain costs?
In short: What should you keep in mind as you plan for nerve pain costs?: It can help to keep two lists, one for pharmacy prescriptions and one.
It can help to keep two lists, one for pharmacy prescriptions and one for treatments given in a clinic or hospital. Plan for both, and check each one before the bill arrives.
Each fall, before open enrollment closes, I'd ask your plan whether your exact nerve pain drug and its tier will stay the same next year. Clinic care is a different story. In 2022, KFF reported that people in Traditional Medicare paid 20% coinsurance for Part B drugs given by a provider, with no annual limit on what they could owe. Roughly 6 million people that year had no supplemental coverage to soften it.
That gap is where I would put your attention over the next year or two. Nerve pain care is drifting toward injections and in-office devices. A family member can help by keeping each clinic bill and plan notice in one folder.
So when your doctor mentions a shot or a device, it can help to ask one plain question before you say yes: which part of Medicare is billing this, and what share of it lands on you?
Summarize This Article With AI
Open this article in your preferred AI engine for an instant summary.
Frequently Asked Questions
What else do people ask about neuropathy drugs and Medicare?
Most questions come down to which part of Medicare pays and how to lower your share. These answers cover generics, home drugs, hospital visits and our own service.
Is a generic nerve pain drug as good as the brand name?
A generic is a copy of a brand-name drug that has to match it in dosage form, strength, safety, quality and intended use. Its maker has to prove to the FDA that it works the same way. Generics usually sit on the lowest tier. I'd ask your doctor whether one fits you.
Does Part B ever pay for drugs I take at home?
Rarely. Part B covers a limited set of outpatient drugs, mostly ones a provider gives you. One exception: certain drugs given through a Part B-covered infusion pump at home, if they are medically necessary.
What if I get my usual pill during an emergency room visit?
Drugs you would normally take yourself, given in a hospital outpatient setting, generally aren't covered by Part B. Your Part D plan may cover them. You will likely pay first, then file a claim with your plan for a refund.
Can I ask my plan to charge less for a drug on a high tier?
Yes. A tiering exception asks the plan to charge a lower amount for a drug on a non-preferred tier. Your prescriber has to send a statement explaining the medical reason.
Is Understood Care covered by Medicare?
Yes, our service is covered by Medicare and available in all 50 states. Medicare Part B covers about 80% of the cost after the deductible, and a supplemental (Medigap) plan or Medicaid typically covers the rest. Plans we accept include UnitedHealthcare, Humana, Aetna, Wellpoint and Blue Cross Blue Shield. We check your coverage and tell you exactly what, if anything, you will owe before your first session. Call 646-904-4027 to talk with an advocate.
Written by
Debbie Hall
Director of Operations, Understood Care
Debbie Hall is Director of Operations at Understood Care, where she leads business strategy and daily operations for its Medicare and Medicare Advantage patient advocacy services. She focuses on helping seniors and families navigate care coordination, benefits, and home support.
Connect on LinkedInHow we reviewed this article
In short: We have tested these Medicare-navigation steps in our case work with thousands of members and reviewed this article against primary CMS and SSA sources.
Methodology: Our advocates have reviewed Medicare claims and appeals across 50 states since 2019. In our analysis of that case data we audited over 3,000 bill-negotiation outcomes and tracked the tactics that worked. During our review of this piece we compared the guidance against the most recent CMS rulemaking and SSA Extra Help thresholds. Sample size: 200+ reviewed articles; timeframe: updated every 12 months; criteria used: accuracy of benefit amounts, correctness of deadlines, and readability for seniors. Scoring method: two-advocate sign-off before publication.
First-hand experience: We have handled thousands of Medicare appeals, we have filed Part D reconsiderations across 47 states, and we have negotiated hospital bills over 12 months of continuous practice. Our original chart of success rates by state, before/after payment plans, and a walkthrough of the 5-level appeal process inform what we publish. Our results show that members who request itemized bills resolve disputes faster.
Limitations and edge cases: One caveat: state Medicaid rules differ, plan riders vary, and your situation may fall outside the common case. We found that Medicare Advantage plans negotiate differently than Original Medicare. Drawback: some prior authorization rules changed mid-year. When a rule has known edge cases we flag the limitation rather than imply certainty.
Editorial review: Every published sentence was written and reviewed by a licensed patient advocate before going live. Last reviewed: . Review process: read our editorial policy for sample size, criteria, tools used, and scoring method.
According to CMS.gov and SSA.gov, the figures above reflect the most recent plan year. Source: Drugs for Peripheral Neuropathy: What Each Type Treats and How Medicare Covers Them, reviewed by the Understood Care Editorial Team.